ivermectin - versus control - for COVID-19 mild to moderate pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.49 [0.01, 26.05]< 10%1 study (1/-)63.4 %some concernnot evaluable moderatecrucial-
deaths 0.43 [0.14, 1.33]< 10%5 studies (5/-)92.8 %highnot evaluable lowcrucial-
clinical deterioration 0.46 [0.26, 0.82]< 10%2 studies (2/-)99.6 %highnot evaluable lowimportant-
clinical improvement 1.72 [1.02, 2.88]> 10%2 studies (2/-)97.9 %highnot evaluable lowimportant-
clinical improvement (7-day) 1.26 [0.68, 2.32]> 182%3 studies (3/-)77.1 %highnot evaluable lowimportant-
clinical improvement (time to event analysis only) 1.89 [1.06, 3.38]> 10%1 study (1/-)98.4 %some concernnot evaluable moderateimportant-
hospital discharge 1.31 [0.83, 2.09]> 10%2 studies (2/-)87.5 %highnot evaluable lowimportant-
mechanical ventilation 0.74 [0.18, 2.99]< 10%3 studies (3/-)66.5 %highnot evaluable lowimportant-
viral clearance 0.93 [0.78, 1.10]> 10%2 studies (2/-)19.3 %highnot evaluable lowimportant-
viral clearance (time to event analysis only) 4.10 [1.12, 14.99]> 10%1 study (1/-)98.3 %highnot evaluable lowimportant-
viral clearance by day 14 3.54 [1.03, 12.13]> 10%2 studies (2/-)97.8 %highnot evaluable lowimportant-
viral clearance by day 7 1.41 [0.71, 2.79]> 177%5 studies (5/-)83.8 %highnot evaluable lowimportant-
ICU admission 0.90 [0.30, 2.70]< 10%1 study (1/-)57.4 %some concernnot evaluable moderatenon important-

safety endpoints 00

serious adverse events 1.49 [0.20, 10.91]< 10%3 studies (3/-)34.8 %highnot evaluable lowimportant-
adverse events 1.52 [0.72, 3.24]< 110%4 studies (4/-)13.7 %highnot evaluable lownon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.